Differential expression of CD10 in prostate cancer and its clinical implication
暂无分享,去创建一个
Lawrence D True | A. Siegel | L. True | Alvin Y. Liu | M. Dall’Era | Marc A Dall'Era | Andrew F Siegel | Alvin Y Liu | Michael P Porter | Tracy M Sherertz | M. Porter | T. Sherertz
[1] Jared C Roach,et al. Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression , 2005, BMC Cancer.
[2] A. Oudes,et al. HSP27 and HSP70 interact with CD10 in C4‐2 prostate cancer cells , 2007, The Prostate.
[3] S. Horvath,et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer , 2003, The Prostate.
[4] D. Goodlett,et al. Stromal mesenchyme cell genes of the human prostate and bladder , 2005, BMC urology.
[5] Takanori Hattori,et al. CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.
[6] R. P. Becker,et al. Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry. , 1997, Anticancer research.
[7] M. Albrecht,et al. Identification and characterization of neutral endopeptidase (EC 3. 4. 24. 11) from human prostasomes–localization in prostatic tissue and cell lines , 2001, The Prostate.
[8] J. Nesland,et al. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression , 2004, Modern Pathology.
[9] U. Rebmann,et al. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. , 1998, International journal of molecular medicine.
[10] A. Belldegrun,et al. Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines , 2004, The Prostate.
[11] Yukihiko Sato,et al. Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon , 1996, Journal of Gastroenterology.
[12] Catherine Magill,et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression , 1998, Nature Medicine.
[13] Jean Kanitakis,et al. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin , 2002, Melanoma research.
[14] L. True,et al. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. , 2004, The American journal of pathology.
[15] A. Roessner,et al. Inhibitory effect of antisense aminopeptidase N (APN/CD13) cDNA transfection on the invasive potential of osteosarcoma cells , 2004, Clinical & Experimental Metastasis.
[16] H. Lilja,et al. Expression and immunolocalisation of neutral endopeptidase in prostate cancer. , 2003, European urology.
[17] J. Manivel,et al. The pattern of CD10 expression in selected pathologic entities of the prostate gland. , 2003, Human pathology.
[18] M. Tatematsu,et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion , 2001, International journal of cancer.
[19] S. Taneja,et al. Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer , 2004, Clinical Cancer Research.
[20] M. Riggs,et al. Stage at presentation and survival of white and black patients with prostate carcinoma , 1993, Cancer.
[21] Leroy Hood,et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Neoptolemos,et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.
[23] K. Pienta,et al. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. , 2000, Journal of the National Cancer Institute.
[24] Lawrence D True,et al. Transcriptomes of human prostate cells , 2006, BMC Genomics.